



**ASX Announcement**  
**10 March 2022**

## **Change of Director's Interest Notice**

**Melbourne, Australia, 10 March 2022:** Optiscan Imaging Limited (ASX: OIL) (**Optiscan** or the Company) provides the attached Appendix 3Y following the issue of unlisted options to the Company's Managing Director, Prof Camile Farah as approved at the Company's Annual General Meeting held on 20 January 2022.

The attached Appendix 3Y also includes an adjustment for an administrative error which was the subject of his Appendix 3X lodged with ASX on 6 May 2021, whereby the initial shareholdings should have totalled 524,985 fully paid ordinary shares for the combined holdings instead of the reported 520,224. In preparing the attached Appendix 3Y it became apparent that there had been an administrative error and this has been updated in the attached Appendix 3Y.

This announcement has been authorised for release by the Board of Optiscan.

### **For investor queries, please contact:**

Robert Cooke  
Non-executive Chairman

### **About Optiscan**

Optiscan is a global leader in the development of microscopic imaging and related technologies for surgery and medical research. Based in Victoria, Australia, Optiscan was established in 1994, and listed on the ASX in 1997 (ASX: OIL). Optiscan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level for cancer screening, diagnoses and in surgery.

### **Disclaimer**

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.*

**Phone** (61 3) 9538 3333

**Website** [www.Optiscan.com](http://www.Optiscan.com)

PO Box 1066, Mt Waverley MDC VIC 3149 Australia

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>OPTISCAN IMAGING LIMITED</b>
<b>ABN</b>	<b>81 077 771 987</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Prof Camile Farah
<b>Date of last notice</b>	6 May 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	1. Phoenix Financial Pty Ltd <Phoenix Super Fund A/C> (Prof Farah is a beneficiary of the fund)  2. Dr Marie Anne Teresa J Matias (Spouse of Prof Farah)
<b>Date of change</b>	9 March 2022
<b>No. of securities held prior to change</b>	1. 500,000 Fully paid ordinary shares 2. 24,985 Fully paid ordinary shares
<b>Class</b>	1. Unlisted options exercisable at \$0.1925 (19.25 cents) on or before 9 March 2025 2. Unlisted options exercisable at \$0.1925 (19.25 cents) on or before 9 March 2027
<b>Number acquired</b>	1. 3,000,000 2. 9,000,000
<b>Number disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<p><b>Direct</b>  3,000,000 Unlisted options exercisable at \$0.1925 (19.25 cents) on or before 9 March 2025  9,000,000 Unlisted options exercisable at \$0.1925 (19.25 cents) on or before 9 March 2027</p> <p><b>Indirect</b></p> <ol style="list-style-type: none"> <li>1. 500,000 Fully paid ordinary shares</li> <li>2. 24,985 Fully paid ordinary shares</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unlisted options following approval sought at the Company's 2021 Annual General Meeting held on 20 January 2022.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.